The leading market experts have placed a mean price target of $36.91 on Myriad Genetics, Inc. (NASDAQ:MYGN) stock. This price level, which is estimated to be attained in one-year indicates the mean of stock opinions given by the companies included in the First Call survey. The renowned research firms have predicted earnings of $0.43 a share for the upcoming quarter and $1.65 for the current fiscal. Technical View The technical analysis of Myriad Genetics, Inc. plainly substantiates that the 50-day moving average of Myriad Genetics, Inc. is $31.11, and stock is hovering -0.24 or -0.77% distant from $31.11. It is noted that the 200-day MA is $35.07, and Myriad Genetics, Inc. stock is $-4.20 or -11.97% off from this point. Myriad Genetics, Inc. (NASDAQ:MYGN) 52-week high is $46.24 and the 52-week low is $28.82. This explains if the stock moves $-15.37, it will post a 52-week high. In event of $+7.11% points decline, a 52-week low will be hit. Taking the Valuation Aspect To emphasize the valuation of Myriad Genetics, Inc., shareholders can apply financial tool known as price-to-earnings ratio. This financial ratio assesses stock’s valuation by considering the relative expense of the stock. Following this ratio, Myriad Genetics, Inc. (NASDAQ:MYGN) ratio came in at 20.86. The stock last ended the trading session at $30.87 and registered a market cap of $2.17B. To appraise firm’s growth, the shareholders take help of the Price-to-Earnings-Growth ratio. When a stock has a higher PEG ratio, it is suggestive of lower stock appreciation in approaching sessions. A stock comes in the group of undervalued stocks when its PEG ratio falls in between 0 and 1. Myriad Genetics, Inc. (NASDAQ:MYGN) PEG ratio is at 1.32.
1 Chart Pattern Every Investor Should Know